International pharmaceutical company, Laboratorios Rubió, announces promising forecasts for economic expansion in 2023, with projections pointing towards growth of 7.5%. The company’s unwavering commitment to innovation and continuous improvement in the healthcare sector has been the driving force behind these positive outlooks.
The impressive growth of Laboratorios Rubió is a testament to its successful strategies and enduring commitment to patient-centered health solutions.
For 2023, the company forecasts an impressive economic trajectory:
The anticipated economic growth is more than just monetary gain, it reflects Laboratorios Rubió’s dedication to offering excellence and exceptional service in the pharmaceutical industry. These positive forecasts are a testament to the hard work and commitment of every team member in the company.
Our growth has been possible thanks to everyone who contributes to this exciting journey, including our employees, collaborators, and stakeholders. They have played a vital role in our success with their support, trust, and commitment, which have fueled our drive for continuous innovation and improvement in the healthcare sector.
The anticipated economic growth is more than just a monetary gain, it reflects Laboratorios Rubió’s dedication to delivering excellence and exceptional service in the pharmaceutical industry. These positive forecasts are a testament to the hard work and commitment of each member of the company’s team.
At Laboratorios Rubió, we are proud to be an integral part of the European pharmaceutical industry, a sector that, as pointed out by Farmaindustria, drives economic growth in Europe by:
Our involvement in the economic expansion of the pharmaceutical industry goes beyond national borders, thanks to our international business with partners in more than 65 countries. As we face changes and challenges, Laboratorios Rubió remains committed to continuing to drive economic growth and improve healthcare globally.
Laboratorios Rubió is a 100% privately owned international pharmaceutical company founded in 1968. Initially, the company aimed to market medicines that were not available in Spain at that time, as they were treatments for low-prevalence diseases. Over the years, Laboratorios Rubió has invested in R&D and developed more than a dozen drugs, many of which are leading treatments for certain diseases or disorders. The company also operates in other areas of health, such as diagnostics and clinical nutrition, and is known for its commitment to sustainable investment in R&D. Laboratorios Rubió has agreements with leading partners in more than 60 countries and has important international certifications such as the FDA.
